Tirzepatide compounding has its own risks, separate from semaglutide's. The doses are larger, concentrations differ between products, and in 2026 FDA took aim at one workaround: adding a vitamin to make a copy look different.
| Ask | Reassuring answer | Warning sign |
|---|---|---|
| Which pharmacy compounds my vial? | A named pharmacy with a license you can look up | "Our partner pharmacy" with no name |
| What is in the vial besides tirzepatide? | A clear ingredient list, with a stated medical reason for anything added | Vitamin "blends" pitched as a feature or a legal workaround |
| What is the concentration? | A mg/mL figure printed on the label | Instructions in units only |
| Who decided my formulation? | Your prescriber, for you | The same "clinical difference" note for every patient |
| Is it the same as Zepbound? | No: made with the drug in Zepbound, not the same product | "Same as Zepbound" or "generic Mounjaro" |
What did FDA say in the Empower warning letter?
The letter went to Empower Clinic Services, LLC, doing business as Empower Pharmacy in Houston, a 503A pharmacy. It names three products, including two tirzepatide/niacinamide vials, and says they "appear to be essentially copies" of FDA-approved tirzepatide and semaglutide products, compounded regularly and in inordinate amounts.
FDA's reasoning is the part to understand. A 503A pharmacy can compound something close to an approved drug if a prescriber determines there is a significant clinical difference for that patient. FDA found orders with no such determination, and determinations that appeared word for word across many records, possibly picked from a menu on a third-party platform. FDA said that undermines the individualized nature of a prescriber's judgment.
The letter also cites insanitary conditions, including inadequate smoke studies of airflow in the sterile area and media-fill tests not run under the most challenging conditions, plus manufacturing-practice violations. Empower had 15 working days to respond.
Why is "tirzepatide plus niacinamide" a warning sign?
Because adding a vitamin does not make a copy meaningfully different, by FDA's account in this letter. When a program advertises "tirzepatide + B3" or "tirzepatide + B12" as something special, ask what clinical reason your prescriber has for the additive. If the answer is a stock phrase, you are looking at the pattern FDA described.
This also matters for side effects: additives change the product, and the Zepbound label's safety data do not cover them.
Where does 503B tirzepatide stand?
Unsettled. FDA announced on April 30, 2026 a proposal not to place tirzepatide, semaglutide or liraglutide on the 503B bulk drug substances list, the list that lets outsourcing facilities compound from bulk ingredients. The comment period was extended to July 30, 2026, and we found no final decision as of November 20, 2026.
In practice, ask whether your vial comes from a 503A pharmacy filling your individual prescription or a 503B outsourcing facility, and check the matching license or FDA registration. Our 503A vs 503B guide explains both.
How can units cause a tirzepatide dosing error?
Tirzepatide doses run from 2.5 mg to 15 mg, and compounded vials come in different strengths. The products named in FDA's Empower letter alone were labeled at 17 mg/mL and 8 mg/mL of tirzepatide. On a U-100 syringe, where 100 units is 1 mL, that difference is large.
| Vial concentration | Volume for 5 mg | U-100 syringe units |
|---|---|---|
| 8 mg/mL | 0.625 mL | 62.5 units |
| 17 mg/mL | about 0.29 mL | about 29 units |
Draw 62 units from the stronger vial and you would get more than twice the intended dose. Four checks prevent that:
- Read the concentration on every new vial, not just the first one.
- Get your dose in milligrams and in units for that specific vial, in writing.
- Have the pharmacy or prescriber confirm the units when your dose or vial changes.
- Use the syringe type the instructions assume; a U-100 syringe is not interchangeable with other markings.
FDA's unapproved GLP-1 page says it had received more than 730 adverse event reports for compounded tirzepatide as of May 31, 2026, and links some reports to dosing errors by patients and by health professionals. The labeled branded ladder is in our tirzepatide dosage chart.
What should you do when the box arrives?
- Check that it is cold. FDA recommends not using injectable GLP-1s that arrive warm.
- Compare the label with your prescription: drug, concentration, pharmacy name and address, beyond-use date.
- Write the first-use date on the vial and discard it 28 days later, even if medication remains, per FDA.
- Use a new sterile needle and syringe for every dose.
- If the liquid looks different from your last vial, call before injecting.
What if your program switches pharmacies?
Programs that list several pharmacies may ship from different ones over time. Treat a new pharmacy name on your label as a new product: look up its license, confirm the concentration, and get your units for that vial in writing before the first draw. Ask the program to tell you in advance when your pharmacy changes, and note the change in your own records with the vial's beyond-use date.
Which programs show the basics?
Among the programs we review, NexLife's plan pages name three state-licensed 503A pharmacies (in Lutz, Florida; Decatur, Alabama; and Lake Charles, Louisiana), and Henry Meds names only the pathway, 503A or 503B. Naming a pharmacy lets you verify it; it does not prove quality. For a wider view of disclosure, see the telehealth GLP-1 transparency index and our NexLife tirzepatide review.
Frequently asked questions
What did FDA find wrong with compounded tirzepatide at Empower Pharmacy?
In warning letter 738238, dated September 18, 2026, FDA said Empower's tirzepatide/niacinamide products appeared to be essentially copies of approved tirzepatide, with missing or copy-paste prescriber determinations of clinical difference and very high volumes. It also cited insanitary conditions in sterile compounding and manufacturing-practice violations. These are FDA's findings in a warning letter, not a court ruling.
Is compounded tirzepatide with B12 or niacinamide better?
There is no trial evidence that it is, and FDA's Empower letter treated adding niacinamide as not making a copy meaningfully different. Additives also take the product further from the branded drug whose safety data you may be relying on. Ask your prescriber for the specific clinical reason before accepting a blend.
Can 503B outsourcing facilities make tirzepatide?
The status is in flux. FDA proposed on April 30, 2026 not to add tirzepatide to the 503B bulk drug substances list and extended the comment period to July 30, 2026. We found no final decision as of November 20, 2026. Ask your program which pathway your vial comes from, and verify it.
How many units is 5 mg of compounded tirzepatide?
It depends entirely on your vial's concentration. On a U-100 syringe, units equal the dose in mg divided by the concentration in mg/mL, times 100. At 8 mg/mL that is 62.5 units; at 17 mg/mL about 29 units. Use the concentration on your own label and have the pharmacy confirm.
Is compounded tirzepatide FDA-approved?
No. FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before sale. Compounded tirzepatide is made with the drug in Zepbound and Mounjaro but is not the same product. The FDA-approved tirzepatide products are Zepbound and Mounjaro, made by Eli Lilly.
Sources
- FDA warning letter 738238: Empower Clinic Services, LLC dba Empower Pharmacy — dated 2026-09-18, posted 2026-09-22; products, findings and concentrations read 2026-11-08
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — content current as of 2026-10-01; read 2026-11-08
- FDA label via DailyMed: Zepbound (tirzepatide) prescribing information — revised 8/2026; dose range read 2026-11-08
- FDA: Compounding and the FDA: Questions and Answers — content current as of 2025-09-16; read 2026-11-08
- Federal Register: FDA proposal on the 503B bulks list for tirzepatide, semaglutide and liraglutide (91 FR 23431; extension 91 FR 38719) — announced 2026-04-30; status per GLPOneReview facts file as of 2026-10-15
- NexLife and Henry Meds program pages — NexLife plan pages read 2026-11-06; Henry Meds read 2026-10-15
Comparing programs? Check the all-in monthly price, the named pharmacy and the cancellation terms on the provider's own page before you pay.
Check NexLife's plans and state availability → See the price index